Last reviewed · How we verify
Phosphoethanolamine
At a glance
| Generic name | Phosphoethanolamine |
|---|---|
| Sponsor | Secretaria de Estado da Saúde |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Evaluation of Synthetic Phosphoethanolamine in Solid Tumor Patients (Phase 2)
- A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Assess Safety and Effectiveness of Liposom in Enhance and Speed up Response With Citalopram in Elderly Patients Suffering (Phase 4)
- The Effect of Soy Lecithin-derived N-oleoyl-phosphatidyl-ethanolamine (NOPE) and Green Tea-derived Epigallocatechin Gallate (EGCG) on Indices of Weight Loss and Appetite Suppression (Phase 1)
- Duodenal Lipid Sensing and Nutrient Absorption (Phase 1)
- Suppression of Endogenous Glucose Production by Injectable HDV-Insulin Lispro: A Dose Response Study in Human Subjects With Type 1 Diabetes (Phase 1)
- Prospective Observational Study of the Expression of ABCB1 / P-glycoprotein as a Factor for the Biological Stratification of Non-metastatic Osteosarcoma of the Extremities (N/A)
- The Gut-brain Axis: a Novel Target for Treating Behavioral Alterations in Obesity (NA)
- An Open Label, Multiple Dose Ranging Trial of AL721 in Patients With Persistent Generalized Lymphadenopathy and Symptomatic HIV Infection (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phosphoethanolamine CI brief — competitive landscape report
- Phosphoethanolamine updates RSS · CI watch RSS
- Secretaria de Estado da Saúde portfolio CI